Immix Biopharma, Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. The filing was signed March 28, 2022. This is an annual report, not a standalone fourth-quarter report.
Business context
Immix is a clinical-stage biopharmaceutical company developing therapies for cancer and inflammatory diseases. It reported no revenue from product sales, collaborations, or licensing. Its lead candidate, IMX-110, was in Phase 1b/2a trials for solid tumors; IMX-111 and IMX-120 were preclinical. The company relies on third-party manufacturers and service providers and had two full-time employees and seven consultants as of March 23, 2022.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $1.35 million | $454,000 |
| Operating loss | $1.35 million | $454,000 |
| Net loss | $24.38 million | $1.15 million |
| Net cash used in operating activities | $1.59 million | $405,000 |
| Cash at year-end | $17.64 million | $391,000 |
- Gross profit and operating margins are not meaningful because the company had no revenue.
- Total assets were $18.19 million and total liabilities were $202,000 at December 31, 2021. Current liabilities included a $50,000 related-party note payable; convertible notes and the associated derivative liability had been eliminated through conversion at the IPO.
- Financing activities provided $18.85 million in 2021, including $18.65 million net IPO proceeds and $200,000 of convertible-note proceeds. The IPO generated an additional $2.91 million net proceeds in January 2022 from the underwriters’ over-allotment option.
- Net loss included a $22.76 million noncash charge from the change in fair value of embedded derivatives in convertible notes, largely reflecting the increased likelihood of a qualifying financing before the notes converted at the IPO. The notes converted into 5,633,689 common shares in December 2021.
Material changes versus 2020
- Net loss increased substantially, primarily due to the derivative fair-value charge and higher general and administrative expenses related to IPO preparation. G&A rose to $1.23 million from $206,000.
- Research and development expense fell to $127,000 from $248,000; the company attributed the decrease to its funding situation. Management expects R&D costs to rise as development expands.
- Operating cash use increased to $1.59 million from $405,000, while cash at year-end rose following the IPO.
- The company completed its IPO in December 2021, with 4.2 million shares sold at $5.00 each. The public listing began on Nasdaq Capital Market in December.
Outlook, clinical programs, and risks
- Management said year-end cash, together with January 2022 over-allotment proceeds, was expected to fund working capital requirements through at least March 31, 2023. The company nevertheless expects significant additional capital needs, has no committed financing source, and warned that unavailable funding could delay, reduce, or stop development. It reported accumulated deficit of $29.76 million and continuing operating losses.
- As of March 2022, 14 patients had been treated in the IMX-110 Phase 1b/2a trial; eight had completed a post-enrollment tumor measurement, and all eight evaluable patients had discontinued treatment. The company reported four-month median progression-free survival among STS patients, no drug-related serious adverse events or toxicity-related dose interruptions to date, and tumor shrinkage in 75% of STS patients. These are early, small-sample, company-reported results and are not proof of efficacy or safety.
- Management planned to treat 30 additional STS patients in a Phase 2a study, with a target duration of about 24 months after first dosing in 2022, and subsequently planned an 80-patient Phase 2b/3 trial. These are plans, not assured timelines.
- For IMX-111, management planned IND-enabling work by mid-2022 and an IND filing in 2023. For IMX-120, it planned IND-enabling work by mid-2022 and an IND filing in 2023. Both candidates remained preclinical.
- IMX-110 received FDA Orphan Drug Designation for soft tissue sarcoma in September 2021. The company also entered a clinical collaboration with BeiGene for a combination trial of IMX-110 and tislelizumab; Immix bears trial and IMX-110 manufacturing costs, while BeiGene supplies tislelizumab. Immix reported no payments to BeiGene as of the filing date.
- Key risks include clinical and regulatory failure or delay, limited patient enrollment, dependence on third-party manufacturers and trial providers, competition, intellectual-property challenges, and the need for further financing. COVID-19 could disrupt trials, suppliers, and regulatory activity.
- Management identified a material weakness in internal control over financial reporting as of year-end, related to limited personnel and insufficient formal review procedures, including journal-entry processing and review. Remediation steps had begun but were not operating long enough to establish that the weakness was resolved. The auditor expressed an unqualified opinion on the financial statements but did not opine on internal-control effectiveness.
- No material legal proceedings were reported. The company disclosed no cash dividends and noted that insiders and principal stockholders beneficially owned approximately 63.94% of shares as of March 23, 2022.
Important facts for investors to verify
- Cash burn, actual runway, and the amount and timing of additional financing required.
- Progress, enrollment, follow-up, safety, and efficacy evidence from IMX-110 trials; distinguish the eight evaluable patients from the 14 treated.
- Whether the planned IMX-110, IMX-111, and IMX-120 development and IND timelines are achieved.
- Manufacturing and clinical-trial execution risks, including the terms and responsibilities under the BeiGene collaboration.
- Whether the identified material weakness is remediated and internal controls operate effectively over time.
- Potential dilution from future financing, outstanding options and warrants, and the effects of concentrated ownership and lock-up expirations.